Disc Medicine (IRON) said Monday that it presented data supporting the advancement of its three investigational drugs.
The company said phase 2 studies showed that its drug candidate bitopertin reduces protoporphyrin IX levels and improves symptoms in adults and adolescents with erythropoietic protoporphyria, a genetic condition that can lead to liver disease.
Updates from pre-clinical studies showed a combination of ruxolitinib with DISC-0974's mouse analog showed potential as a treatment for anemia in myelofibrosis and inflammatory bowel disease, according to the company.
The company also said that DISC-3405 reduced serum iron levels and was well-tolerated in healthy volunteers, suggesting potential for treating polycythemia vera and sickle cell disease.
Shares of the company were down 1.5% in recent trading.
Price: 63.88, Change: -0.94, Percent Change: -1.45
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。